CN110679948A - 使用人乳寡糖用于调节炎症的营养制剂 - Google Patents
使用人乳寡糖用于调节炎症的营养制剂 Download PDFInfo
- Publication number
- CN110679948A CN110679948A CN201911070370.1A CN201911070370A CN110679948A CN 110679948 A CN110679948 A CN 110679948A CN 201911070370 A CN201911070370 A CN 201911070370A CN 110679948 A CN110679948 A CN 110679948A
- Authority
- CN
- China
- Prior art keywords
- nutritional
- nutritional composition
- composition
- concentration
- neutral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 251
- 239000000203 mixture Substances 0.000 title claims abstract description 205
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 42
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 41
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 37
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 36
- 235000020256 human milk Nutrition 0.000 title claims abstract description 33
- 210000004251 human milk Anatomy 0.000 title claims abstract description 29
- 238000009472 formulation Methods 0.000 title description 16
- 230000007935 neutral effect Effects 0.000 claims abstract description 85
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 24
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 24
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 24
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims description 20
- 235000021466 carotenoid Nutrition 0.000 claims description 20
- 150000001747 carotenoids Chemical class 0.000 claims description 20
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 18
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 18
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 17
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 17
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 230000000241 respiratory effect Effects 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims description 7
- 238000004977 Hueckel calculation Methods 0.000 description 98
- 239000007788 liquid Substances 0.000 description 70
- 239000000047 product Substances 0.000 description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 239000000843 powder Substances 0.000 description 38
- 201000010099 disease Diseases 0.000 description 37
- 239000004615 ingredient Substances 0.000 description 35
- 239000003925 fat Substances 0.000 description 33
- 235000019197 fats Nutrition 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 238000000034 method Methods 0.000 description 30
- 235000014633 carbohydrates Nutrition 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 28
- 150000001720 carbohydrates Chemical class 0.000 description 28
- 239000000839 emulsion Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 22
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 239000000835 fiber Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 18
- 235000013305 food Nutrition 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 16
- 239000003963 antioxidant agent Substances 0.000 description 15
- 230000008901 benefit Effects 0.000 description 15
- 235000012054 meals Nutrition 0.000 description 15
- 239000002002 slurry Substances 0.000 description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 229920002148 Gellan gum Polymers 0.000 description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 14
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 14
- 235000010492 gellan gum Nutrition 0.000 description 14
- 239000000216 gellan gum Substances 0.000 description 14
- 229940088594 vitamin Drugs 0.000 description 14
- 229930003231 vitamin Natural products 0.000 description 14
- 235000013343 vitamin Nutrition 0.000 description 14
- 239000011782 vitamin Substances 0.000 description 14
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 13
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 12
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 229960004999 lycopene Drugs 0.000 description 12
- 239000011707 mineral Substances 0.000 description 12
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 11
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 240000008042 Zea mays Species 0.000 description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 11
- 229940077731 carbohydrate nutrients Drugs 0.000 description 11
- 235000005822 corn Nutrition 0.000 description 11
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 11
- 235000012661 lycopene Nutrition 0.000 description 11
- 239000001751 lycopene Substances 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 11
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 10
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 10
- 235000013734 beta-carotene Nutrition 0.000 description 10
- 239000011648 beta-carotene Substances 0.000 description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 10
- 229960002747 betacarotene Drugs 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 229960005375 lutein Drugs 0.000 description 10
- 235000012680 lutein Nutrition 0.000 description 10
- 239000001656 lutein Substances 0.000 description 10
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 10
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 10
- 229920002774 Maltodextrin Polymers 0.000 description 9
- 239000005913 Maltodextrin Substances 0.000 description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 9
- 235000010418 carrageenan Nutrition 0.000 description 9
- 229920001525 carrageenan Polymers 0.000 description 9
- 239000000679 carrageenan Substances 0.000 description 9
- 229940113118 carrageenan Drugs 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 9
- 229960000304 folic acid Drugs 0.000 description 9
- 235000019152 folic acid Nutrition 0.000 description 9
- 239000011724 folic acid Substances 0.000 description 9
- 229940035034 maltodextrin Drugs 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 9
- 230000002195 synergetic effect Effects 0.000 description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 9
- 102000014171 Milk Proteins Human genes 0.000 description 8
- 108010011756 Milk Proteins Proteins 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000021239 milk protein Nutrition 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000002562 thickening agent Substances 0.000 description 8
- 244000075850 Avena orientalis Species 0.000 description 7
- 235000007319 Avena orientalis Nutrition 0.000 description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 7
- 235000021342 arachidonic acid Nutrition 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 229960004106 citric acid Drugs 0.000 description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 235000007715 potassium iodide Nutrition 0.000 description 7
- 229960004839 potassium iodide Drugs 0.000 description 7
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 7
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 7
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 7
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 7
- 235000019192 riboflavin Nutrition 0.000 description 7
- 239000002151 riboflavin Substances 0.000 description 7
- 229960002477 riboflavin Drugs 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 6
- 235000007558 Avena sp Nutrition 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 6
- 102100022338 Integrin alpha-M Human genes 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 6
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- 235000019742 Vitamins premix Nutrition 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 6
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 6
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 6
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229910000365 copper sulfate Inorganic materials 0.000 description 6
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 6
- 235000005687 corn oil Nutrition 0.000 description 6
- 239000002285 corn oil Substances 0.000 description 6
- 239000011666 cyanocobalamin Substances 0.000 description 6
- 229960002104 cyanocobalamin Drugs 0.000 description 6
- 235000000639 cyanocobalamin Nutrition 0.000 description 6
- -1 elixir Substances 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- 235000019175 phylloquinone Nutrition 0.000 description 6
- 239000011772 phylloquinone Substances 0.000 description 6
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 6
- 229960001898 phytomenadione Drugs 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 235000019172 retinyl palmitate Nutrition 0.000 description 6
- 239000011769 retinyl palmitate Substances 0.000 description 6
- 229940108325 retinyl palmitate Drugs 0.000 description 6
- 239000003813 safflower oil Substances 0.000 description 6
- 235000011888 snacks Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 6
- 235000005282 vitamin D3 Nutrition 0.000 description 6
- 239000011647 vitamin D3 Substances 0.000 description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 229940021056 vitamin d3 Drugs 0.000 description 6
- 235000010930 zeaxanthin Nutrition 0.000 description 6
- 239000001775 zeaxanthin Substances 0.000 description 6
- 229940043269 zeaxanthin Drugs 0.000 description 6
- 108010076119 Caseins Proteins 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 5
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 5
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 description 5
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 5
- 235000019484 Rapeseed oil Nutrition 0.000 description 5
- 235000019485 Safflower oil Nutrition 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229960004203 carnitine Drugs 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 5
- LJAOOBNHPFKCDR-UHFFFAOYSA-K chromium(3+) trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cr+3] LJAOOBNHPFKCDR-UHFFFAOYSA-K 0.000 description 5
- 239000003240 coconut oil Substances 0.000 description 5
- 235000019864 coconut oil Nutrition 0.000 description 5
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 5
- 229940107029 ferrous sulfate,dried Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 5
- 229940012843 omega-3 fatty acid Drugs 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 150000004686 pentahydrates Chemical class 0.000 description 5
- 239000001508 potassium citrate Substances 0.000 description 5
- 229960002635 potassium citrate Drugs 0.000 description 5
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 5
- 235000011082 potassium citrates Nutrition 0.000 description 5
- 235000005713 safflower oil Nutrition 0.000 description 5
- MHQOTKLEMKRJIR-UHFFFAOYSA-L sodium selenate Chemical compound [Na+].[Na+].[O-][Se]([O-])(=O)=O MHQOTKLEMKRJIR-UHFFFAOYSA-L 0.000 description 5
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 5
- 229940071440 soy protein isolate Drugs 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- 150000005846 sugar alcohols Chemical class 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- 229940118149 zinc sulfate monohydrate Drugs 0.000 description 5
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 4
- 235000019743 Choline chloride Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 239000004376 Sucralose Substances 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 229960002079 calcium pantothenate Drugs 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 4
- 229960003178 choline chloride Drugs 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000014510 cooky Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000009969 flowable effect Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000006014 omega-3 oil Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019408 sucralose Nutrition 0.000 description 4
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 229940078499 tricalcium phosphate Drugs 0.000 description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 241000193163 Clostridioides difficile Species 0.000 description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 235000010582 Pisum sativum Nutrition 0.000 description 3
- 240000004713 Pisum sativum Species 0.000 description 3
- 244000134552 Plantago ovata Species 0.000 description 3
- 235000003421 Plantago ovata Nutrition 0.000 description 3
- 239000009223 Psyllium Substances 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 230000007416 antiviral immune response Effects 0.000 description 3
- 239000008122 artificial sweetener Substances 0.000 description 3
- 235000021311 artificial sweeteners Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000014171 carbonated beverage Nutrition 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 description 3
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000012263 liquid product Substances 0.000 description 3
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 235000006180 nutrition needs Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940070687 psyllium Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000009561 snack bars Nutrition 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 229940083466 soybean lecithin Drugs 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000005457 triglyceride group Chemical group 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- XCVWCSLKKQOBGY-UHFFFAOYSA-N 2-acetyl-4-aminobenzenesulfonic acid Chemical compound CC(=O)C1=CC(N)=CC=C1S(O)(=O)=O XCVWCSLKKQOBGY-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000273930 Brevoortia tyrannus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002245 Dextrose equivalent Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000001422 FEMA 4092 Substances 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 240000003183 Manihot esculenta Species 0.000 description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920000034 Plastomer Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 241000790234 Sphingomonas elodea Species 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000021536 Sugar beet Nutrition 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000010358 acesulfame potassium Nutrition 0.000 description 2
- 229960004998 acesulfame potassium Drugs 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229940108928 copper Drugs 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- IERHLVCPSMICTF-ZAKLUEHWSA-N cytidine-5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-ZAKLUEHWSA-N 0.000 description 2
- 239000013530 defoamer Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 235000010598 long-chain omega-6 fatty acid Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000020166 milkshake Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DJJCXFVJDGTHFX-ZAKLUEHWSA-N uridine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-ZAKLUEHWSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical group OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241001559187 Human rubulavirus 2 Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 230000005353 IP-10 production Effects 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- BRHHWBDLMUBZQQ-JZEMXWCPSA-N Lactodifucotetraose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H](O)[C@H](O)CO)[C@H](C=O)O[C@@H]1[C@H](O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 BRHHWBDLMUBZQQ-JZEMXWCPSA-N 0.000 description 1
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 101100185408 Mus musculus Mug2 gene Proteins 0.000 description 1
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-PGIATKPXSA-N N-glycoloylneuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000269980 Pleuronectidae Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 1
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 235000009767 bottled carbonated water Nutrition 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000000641 cold extrusion Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021183 entrée Nutrition 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 238000001192 hot extrusion Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- RQNFGIWYOACERD-UHFFFAOYSA-N lacto-N-Difucosylhexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O RQNFGIWYOACERD-UHFFFAOYSA-N 0.000 description 1
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 description 1
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 1
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 1
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 description 1
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940107604 lutein esters Drugs 0.000 description 1
- 150000002658 luteins Chemical class 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019976 tricalcium silicate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000014107 unsaturated dietary fats Nutrition 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0612—Carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/154—Water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1578—Calcium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1586—Chromium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1588—Copper
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1592—Iron
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1598—Iodine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/16—Potassium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1608—Molybdenum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/161—Magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1612—Manganese
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1614—Sodium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1626—Selenium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1642—Zinc
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1842—Lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/304—Choline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5036—Carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5054—Gellan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5108—Cellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
- A23V2250/54246—Casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
- A23V2250/54252—Whey protein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/548—Vegetable protein
- A23V2250/5488—Soybean protein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/61—Glucose, Dextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/628—Saccharose, sucrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/702—Vitamin A
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7044—Vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7046—Vitamin B3 niacin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/705—Vitamin B5 pantothenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7056—Vitamin B8 Folic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7058—Vitamin B9
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/706—Vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/71—Vitamin D
- A23V2250/7106—Vitamin D3
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/712—Vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/72—Biotin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pediatric Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
公开了用于调节或减少需要其的成人或老年个体中的炎症的营养组合物。在一些方面中,所述营养组合物包含中性人乳寡糖。
Description
本申请是申请日为2013年12月20日,申请号为201380067062.8,发明名称为“使用人乳寡糖用于调节炎症的营养制剂”的发明专利申请的分案申请。
本申请要求2012年12月20日提交的第61/739,923号美国临时申请的优先权和任何权益,其整体内容以它的整体通过引用并入。
技术领域
本公开涉及用于调节或减少需要其的成人或老年个体中的炎症的营养组合物。更特别地,在一些方面中,营养组合物通过减少血小板嗜中性粒细胞复合物(PNC)形成减少炎症和炎性疾病的发病率。在一些方面中,营养组合物包含中性人乳寡糖。
背景技术
炎性反应是身体在感染物侵袭、抗原攻击或物理、化学或创伤性损伤后试图恢复和维持动态平衡。虽然炎性反应一般视为对损伤所作出的有益健康的反应,但如果免疫系统未得到适当地调节则其可能会出现不良生理反应。特别地,例如,未调节的氧化和相关炎症是成人和老年人,肿瘤患者中的组织损伤和临床严重疾病的主要原因。
包含HMOs的母乳与婴儿呼吸、胃肠和免疫系统的发育增强及生长和成熟平衡相关,由此保护婴儿免于感染和炎性疾病。除外源性抗氧化剂如维生素A、C、E和硒外,母乳似乎还含有内源性抗氧化剂,如超氧化物歧化酶、谷胱甘肽过氧化物酶和触酶,或其他非酶抗氧化剂,如谷胱甘肽、乳铁蛋白和多酚。此外,母乳包括HMOs,其不仅充当病原体受体类似物,而且活化免疫因子。这些充当抗氧化剂和免疫调节剂的母乳组分的功能不仅包括保护母乳脂质免于过氧化,而且可有助于调节针对感染或其他损伤的炎性反应。
目前没有疫苗可用于炎性疾病的最小化。因此,安全和有效的预防性或治疗性方法的发展将是有益的,尤其是对于成人和老年人。因此,期望提供可产生营养益处包括提高的免疫系统支持和反应的营养组合物且特别地成人营养组合物配方产品。此外,如果营养组合物可调节炎症并且增强对微生物感染,包括细菌和病毒感染以及其他炎性疾病的免疫力将是有益的。
发明内容
在一个方面中,本公开涉及用于调节或减少需要其的成人或老年个体中的炎症的营养组合物,所述营养组合物包含浓度为约0.001 mg/mL至约25 mg/mL的中性人乳寡糖。特别适用于营养组合物的中性HMOs包含下列的至少一种:2'-岩藻糖基乳糖(2'FL)和乳酰-N-新四糖(LNnT),且特别地,2'FL和3-岩藻糖基乳糖(3FL)的组合,以及3FL和LNnT的组合。
附图说明
图1. 证实2'FL和FL混合物显著减少PNC形成。15分钟孵育是最佳的。
具体实施方案
术语“蒸煮包装”和“蒸煮灭菌”在本文可交换地使用,并且除非另外规定,是指如下常用操作:使用营养液体填充容器,最通常地金属罐或其他类似包装,然后使液体填充的包装进行必要的热灭菌步骤以形成经灭菌、蒸煮包装的营养液产品。
除非另外规定,如本文中所使用,术语“无菌包装”是指不依靠上述蒸煮包装步骤来制造包装产品,其中营养液和包装在填充之前分别进行灭菌,然后在灭菌或无菌处理条件下组合以形成经灭菌、无菌包装的营养液产品。
除非另外规定,如本文中所使用,术语“脂肪”和“油”可互换用于指来源于植物或动物或由植物或动物加工的脂质物质。这些术语也包括合成脂质物质,只要这些合成物质适于口服给予人类。
除非另外规定,如本文中所使用,术语“人乳寡糖”或“HMO”一般是指存在于人母乳中的许多复杂碳水化合物,其可呈酸性或中性形式,以及是指其前体。示例性非限制性中性人乳寡糖包括3-岩藻糖基乳糖、2'-岩藻糖基乳糖和乳酰-N-新四糖(LNnT)。示例性人乳寡糖前体包括乳糖、岩藻糖或其任意组合。“中性人乳寡糖”通常是指由单糖组成的在生理学pH下不带电的中性寡糖,即不包含唾液酸(N-乙酰基-神经氨酸或N-羟乙酰基-神经氨酸)的残基或部分并且还缺乏葡萄糖胺(即,非乙酰基化葡萄糖胺)。中性HMOs的浓度范围可为约0.001 mg/mL至约25 mg/mL。因此,2'-岩藻糖基乳糖的重量范围的实例可为约0.001 mg/mL至约25 mg/mL;且LNnT可为约0.001 mg/mL至约25 mg/mL。
除非另外规定,如本文中所使用,术语“贮存稳定”是指营养产品,其经包装然后在18-24℃下储存至少3个月(包括约6个月至约24个月,并且也包括约12个月至约18个月)后保持商业稳定。
如本文中所使用,术语“营养制剂”或“营养组合物”可互换使用且除非另外规定,是指合成配方产品,包括营养液、营养粉、营养固体、营养半固体、营养半液体、营养补充剂和如本领域中已知的任何其他营养食品。营养粉可重构形成营养液,其均包含脂肪、蛋白质和碳水化合物的一种或多种,并且适合人口服食用。术语“营养制剂”或“营养组合物”不包括人母乳。
除非另外规定,如本文中所使用,术语“营养液”是指呈即饮型液体形式、浓缩形式的营养产品,和通过在使用之前重构本文所述的营养粉所制得的营养液。
除非另外规定,如本文中所使用,术语“营养粉”是指呈可流动或可舀取形式的营养产品,其可在食用之前用水或另一水性液体重构且包括喷雾干燥和干混/干掺的粉末。
除非另外规定,如本文中所使用,术语“营养半固体”是指性质(如刚性)介于固体与液体之间的营养产品。一些半固体实例包括布丁、明胶和面团。
除非另外规定,如本文中所使用,术语“营养半液体”是指性质(如流动性质)介于液体与固体之间的营养产品。一些半液体实例包括奶昔(thick shakes)和液体凝胶。
如本文中所使用,术语“成人”是指成人和儿童,其为约12岁和更大。
如本文中所使用,术语“老年个体”是指年龄为至少45岁,包括年龄为至少50岁、年龄为至少55岁、年龄为至少60岁、年龄为至少65岁、年龄为至少70岁、年龄为至少75岁,并且包括年龄为至少80岁或更大的个体。术语“老年人”还包括年龄为约45岁至年龄为约95岁的组,和年龄为约55岁至年龄为约80岁的组。
除非另外规定,如本文中所使用,关于诱导产生来源于单核细胞的细胞因子的术语“病毒不存在(absence of a virus)”或“不存在病毒(absent a virus)”是指个体无病毒或所具有的病毒量小于引起免疫反应所需的量;即,该量小于身体天然免疫反应增加细胞因子及其他免疫因子产生所需的量。
除非另外规定,如本文中所使用,术语“炎性疾病”或“炎性疾病状态”是指特征为炎症的任何疾病、病症或疾病状态。除非另外规定,如本文中所使用,术语“感染介导性炎性疾病”是指与微生物感染(包括病毒和细菌感染)相关或由其诱导的炎性疾病。
除非另外规定,如本文中所使用,术语“易患”和“处于风险中”意指对某种疾病状态或疾病具有极小抗性,包括具有该疾病状态或疾病的遗传倾向、具有其家族史和/或具有其症状。
除非另外规定,如本文中所使用,术语“调节(modulating)”或“调节(modulation)”或“调节(modulate)”是指对所选特征的目标动作。
除非另外规定,如本文中所使用,术语“改善”意指消除、延迟或降低与疾病状态有关的症状的患病率或严重程度。
术语“有效量”意图限制HMO的量,其实现降低患者遭受不良健康事件的风险的目标,同时避免不利副作用如通常与替代疗法有关的那些。有效量可在一个或多个剂量中给予。
除非另外规定,如本文中所使用,术语“治疗(treating)”和“治疗(treatment)”,包括延迟疾病状态的发作、降低疾病状态的症状的严重程度,或消除疾病状态的一些或所有症状。
除非另外规定,如本文中所使用,术语“病毒生长”或“细菌生长”是指病毒或细菌的产生、增殖或复制。
如本文中所使用,术语“食品”是指包含脂肪、氨基氮和碳水化合物的一种或多种并且以推荐的每日量提供患者一些或所有营养支持的递送介质。频繁地,食品包含维生素、矿物质、痕量矿物质等以提供正餐替代品、医疗食品、补充剂平衡的营养。食品可为任何典型形式如饮料、粉末、棒、果汁、充气饮料、瓶装水。
除非另外规定,如本文中所使用,所有百分数、份数和比例均以总组合物的重量计。除非另外规定,所有此类重量在其关于所列成分时是指基于活性物水平且因此不包括可包括于市售物质中的溶剂或副产物。
如本文中所使用,数值范围意图包括该范围内的每一数目和数目的子集,无论是否特定地公开。此外,这些数值范围应视为对针对该范围内的任何数目或数目的子集的主张提供支持。例如,1至10的公开应视为支持2至8、3至7、5至6、1至9、3.6至4.6、3.5至9.9等范围。
除非另外规定或所提及的上下文相反地清楚暗示,所有对本公开单数特征或限制的提及均应包括相应复数特征或限制,反之亦然。
除非另外规定或提及组合的上下文相反地清楚暗示,如本文中所使用,方法或过程步骤的所有组合均可以任何顺序进行。
PNC(血小板嗜中性粒细胞复合物)形成的减少表示炎症的减少。现有文献显示酸性寡糖的合并混合物减少PNC形成。现有文献还显示中性寡糖的合并混合物并不减少PNC形成,或减少CD11b表达。与现有结果相反,本文提供的实验结果显示单独地或结合3-岩藻糖基乳糖(3FL)的单个中性人乳寡糖2'-岩藻糖基乳糖(2'FL)和乳酰-N-新四糖(LNnT)减少PNC形成。此外,单独的3FL并不减少PNC形成。与现有结果进一步相反并且与中性寡糖的结果相反,本文提供的结果显示酸性HMOs 3'-唾液酸乳糖(3'SL)和6'-唾液酸乳糖(6'SL)并不减少PNC形成;并且酸性HMO前体唾液酸(SL)也不减少PNC形成。
发现特定中性HMOs如2'-岩藻糖基乳糖和乳酰-N-新四糖,以及2'-和3-岩藻糖基乳糖的组合对抑制通常在成人中的炎症,并且特别地抑制病毒诱导的炎症,包括呼吸道合胞体病毒、人类副流感病毒和甲型流感高度有效,其通过减少从人免疫细胞产生一些关键细胞因子而不增加病毒载量起作用,这可导致从感染的更快恢复。
PNC形成(血小板-嗜中性粒细胞复合物)增加,因此炎症增加并且其可能受益于炎症的减少的群体包括糖尿病患者,特别是女性,缺血患者、活性镰状细胞病患者、具有血管炎症的患者,和患有微生物感染(呼吸道或胃肠感染、败血症、牙周炎)的患者。其他益处为处于慢性炎症风险的那些成人和老年个体。这可包括也可受益于PNC形成和引起的炎症的减少的运动员、老年人、具有哮喘或过敏症的那些和具有炎性肠病(IBD)的那些。
出人意料地,确定这些中性HMOs显示期望的抑制作用,即使在非常低的浓度下,包括低于在人母乳中发现的那些的浓度。
此外,发现当结合长链多不饱和脂肪酸和/或类胡萝卜素时,特定中性HMOs以协同方式对呼吸道病毒包括RSV起作用。这些协同作用抑制病毒诱导的炎性细胞因子,并且特别地干扰素-可诱导蛋白10(IP-10)。还可将包括抗氧化剂如维生素A和维生素E或核苷酸的其他组分添加至HMO(s)和长链多不饱和脂肪酸和/或类胡萝卜素组合。
还发现,中性HMO 2'-岩藻糖基乳糖以及2'-岩藻糖基乳糖和3-岩藻糖基乳糖的混合物减少血小板嗜中性粒细胞复合物(PNC)形成。此外,LNnT减少2/3个体中的PNC形成。
本文描述的营养组合物和方法使用单独地或结合长链多不饱和脂肪酸、抗氧化剂包括类胡萝卜素和核苷酸的一种或多种的中性HMOs用于控制和减少与炎症有关的疾病和疾病状态的数量。在一些方面中,本文描述的营养组合物包括包含一种中性HMO、中性HMOs的组合、或一种或多种中性HMOs与长链多不饱和脂肪酸、抗氧化剂包括类胡萝卜素和核苷酸的一种或多种的组合的合成配方产品。营养组合物、其方法及用途的这些和其他特征以及许多任选变型和添加物中的一些在下文详细地描述。
可在合适的组合物中配制中性HMOs,然后根据本发明的方法,以适应于选择的给药途径的形式给予患者。制剂包括但不限于适用于口服或肠胃外(包括皮下、肌内、腹膜内、瘤内和静脉内)给药的那些。本文定义的口服给药包括其中中性HMO穿过患者的食道的任何给药形式。例如,口服给药包括鼻胃管置入,其中管穿过鼻子进入患者的胃以给予食物或药物。
口服制剂包括适用于本文的任何固体、液体或粉末制剂,条件是这种制剂允许安全和有效口服递送中性HMO和任选的营养成分。在优选的实施方案中,口服制剂为液体营养组合物。适用于口服给药的本发明的制剂可以分开单位如片剂、锭剂、胶囊剂、糖锭剂、薄片剂或扁囊剂形式提供,其各自包含预定量的粉末或颗粒形式或在水性液体或非水性液体中的溶液或悬浮液形式如糖浆剂、酏剂、乳剂或饮剂形式的中性HMO。
营养组合物和方法可包括、由下列组成、或基本上由下列组成:本文描述的组合物和方法的必需元素,以及本文描述的或另外可用于营养产品应用的任何另外或任选元素。
人乳寡糖
本公开的营养组合物包含至少一种中性HMO,并且在许多实施方案中,两种或更多种中性HMOs的组合。寡糖为人母乳的主要成分之一,其包含,平均10克每升的中性寡糖和1克每升的酸性寡糖。人乳寡糖的组合物非常复杂并且已知多于200种不同的寡糖样结构。
可从由哺乳动物分泌的乳中分离或富集中性HMO或HMOs,所述哺乳动物包括但不限于:人、牛、绵羊、猪或山羊种类。中性HMOs还可通过微生物发酵、酶促方法、化学合成或其组合产生。
用于营养组合物的合适的中性HMOs包括岩藻糖基寡糖(即,乳酰-N-岩藻五糖I;乳酰-N-岩藻五糖II;乳酰-N-岩藻五糖III;乳酰-N-二岩藻六糖I;和乳酰二岩藻四糖);非岩藻糖基化、非唾液酸化寡糖(即,乳酰-N-四糖和乳酰-N-新四糖)。特别适用于营养组合物的中性HMOs包括下列HMOs或HMO前体的至少一种:2'-岩藻糖基乳糖(2'FL);3-岩藻糖基乳糖(3FL);乳酰-N-四糖(LNT)和乳酰-N-新四糖(LNnT),且特别地,2'FL和3FL的组合;以及3FL和LNnT的组合。除了上述中性HMOs之外,营养组合物可包含其他中性HMOs、酸性HMOs,或本领域已知的酸性或中性HMO前体。
中性HMOs以如下中性HMO在组合物中的总量(中性HMO的mg/组合物的mL)存在于营养组合物中:至少约0.001 mg/mL、包括至少约0.01 mg/mL、并且还包括约0.001 mg/mL至约25 mg/mL、包括约0.01 mg/mL至约20 mg/mL、包括约0.01 mg/mL至约10 mg/mL、包括约0.01mg/mL至约5 mg/mL、包括约0.01 mg/mL至约1 mg/mL、并且还包括约0.001 mg/mL至约1 mg/mL、包括约0.001 mg/mL至约0.23 mg/mL、包括约0.01 mg/mL至约0.23 mg/mL的总中性HMO在营养组合物中的量。通常,营养组合物中的中性HMO的量依赖存在的具体中性HMO或中性HMOs和营养组合物中其他组分的量。
在一个特殊的实施方案中,营养组合物包含约0.001 mg/mL至约25 mg/mL、包括约0.001 mg/mL至小于约2 mg/mL、并且还包括约0.01 mg/mL至约25 mg/mL、包括约0.01 mg/mL至小于约2 mg/mL的量的中性人乳寡糖。
在另一实施方案中,营养组合物包含一种或多种选自2'-岩藻糖基乳糖和乳酰-N-新四糖的中性人乳寡糖。
在一个特殊的实施方案中,营养组合物包含浓度为约0.001 mg/mL至约25 mg/mL、包括约0.001 mg/mL至小于0.2 mg/mL、还包括约0.01 mg/mL至约25 mg/mL、包括约0.01mg/mL至小于约0.2 mg/mL、并且还包括大于约0.32 mg/mL至约20 mg/mL、并且还包括约0.1mg/mL至约5 mg/mL的单独的或结合其他HMOs的LNnT。
在另一特殊的实施方案中,营养组合物包含约0.001 mg/mL至约25 mg/mL、包括约0.001 mg/mL至约15 mg/mL、包括约0.001 mg/mL至小于约2 mg/mL、包括约0.001 mg/mL至小于约1 mg/mL、还包括约0.01 mg/mL至约25 mg/mL、包括约0.01 mg/mL至约20 mg/mL、包括约0.01 mg/mL至小于约2 mg/mL、包括约0.01 mg/mL至小于约1 mg/mL、并且还包括大于1.7 mg/mL至约20 mg/mL、包括大于约2.5 mg/mL至约20 mg/mL、并且还包括约0.050 mg/mL至约10 mg/mL、包括约0.1 mg/mL至约10 mg/mL的量的单独的或结合其他HMOs的2'FL。
在一个特殊的实施方案中,营养组合物以约0.001 mg/mL至约25 mg/mL、包括约0.01 mg/mL至约25 mg/mL的总HMO的HMO的总量包含2'FL或LNnT,其与3FL组合,其中3FL以约0.001 mg/ML至约10 mg/mL的浓度存在于营养组合物中。
长链多不饱和脂肪酸(LCPUFAs)
除了上述HMOs之外,本公开的营养产品可包含LCPUFAs。LCPUFAs包括在营养组合物中以提供营养支持,以及减少氧化应激和增强肠道上皮及相关免疫细胞群体的生长和功能发育。在一些实施方案中,营养组合物包括一种或多种中性HMOs与一种或多种LCPUFAs的组合以使得该组合物向最终使用者提供协同益处,如调节抗病毒免疫反应和阻抑炎症的协同益处。
用于营养组合物中的示例性LCPUFAs包括例如ω-3 LCPUFAs和ω-6 LCPUFAs。特定LCPUFAs包括二十二碳六烯酸(DHA)、二十碳五烯酸(EPA)、二十二碳五烯酸(DPA)、花生四烯酸(ARA)、亚油酸、亚麻酸(α亚麻酸)和γ-亚麻酸,其源自油源(如植物油、海洋浮游生物、真菌油、磷虾油和鱼油)。在一个特定实施方案中,LCPUFAs来源于鱼油,如鲱鱼(menhaden)、鲑鱼、鲚鱼、鳕鱼、大比目鱼、鲔鱼或青鱼(herring)油。与中性HMOs一起用于营养组合物中的尤其优选的LCPUFAs包括DHA、ARA、EPA、DPA及其组合。
为了减少营养组合物中高剂量LCPUFAs的潜在副作用,LCPUFAs的含量优选不超过营养组合物中总脂肪含量的3重量%,包括低于总脂肪含量的2重量%,且包括低于总脂肪含量的1重量%。
LCPUFA可以游离脂肪酸形式、甘油三酯形式、甘油二酯形式、甘油单酯形式、磷脂形式、酯化形式或以上述中一种或多种的混合物形式提供,优选以甘油三酯形式提供。
如本文所述的营养组合物通常将包含总浓度为约0.01 mM至约10 mM且包括约0.01 mM至约1 mM的LCPUFA。或者,营养组合物包含总浓度为约0.001 g/L至约1 g/L的LCPUFA。
在一个实施方案中,营养组合物包括浓度为约100至约425 mg/L或每100 kcals约12至约53 mg的总长链ω-6 脂肪酸和/或另外包括浓度为约40至约185 mg/L或每100kcals约5至约23 mg的总长链ω-3 脂肪酸。在一个特定实施方案中,营养组合物中长链ω-6 脂肪酸与长链ω-3 脂肪酸的比例在约2:1至约3:1的范围内,优选约2.5:1。
在一个特定实施方案中,营养组合物包括浓度为约0.025 mg/mL至约0.130 mg/mL或每100 kcals约3至约16 mg的DHA。在另一实施方案中,营养组合物包括浓度为约0.080mg/mL至约0.250 mg/mL或每100 kcals约10至约31 mg的ARA。在又一实施方案中,营养组合物包括使得DHA与ARA的比例在约1:4至约1:2的范围内的DHA与ARA的组合。
抗氧化剂
另外,营养组合物可包含一种或多种抗氧化剂与中性HMOs的组合(且还任选包含LCPUFAs和/或核苷酸)以提供营养支持,以及减少氧化应激。在一些实施方案中,营养组合物包括中性HMOs与抗氧化剂的组合以使得该组合物向最终使用者提供协同益处,如调节抗病毒免疫反应和阻抑炎症的协同益处。在一些实施方案中,类胡萝卜素用作抗氧化剂(且具体地叶黄素、β-胡萝卜素、玉米黄素和/或番茄红素)以提供协同作用。
可包含任何适于口服给药的抗氧化剂用于本公开的营养组合物,例如包括例如,维生素A、维生素E、维生素C、视黄醇、生育酚和类胡萝卜素,包括叶黄素、β-胡萝卜素、玉米黄素和番茄红素及其组合。
如上所述,用于营养组合物中的抗氧化剂可与单独中性HMOs一起使用或与中性HMOs和LCPUFAs和/或核苷酸的组合一起使用。在一个特定实施方案中,用于营养组合物中的抗氧化剂包括类胡萝卜素,且尤其是类胡萝卜素叶黄素、番茄红素、玉米黄素和/或β-胡萝卜素的组合。如本文所选和所定义的含有这些组合的营养组合物可用于调节炎症和/或C反应性蛋白的水平。
通常优选地,营养组合物包含至少一种选自叶黄素、番茄红素、玉米黄素和β-胡萝卜素的类胡萝卜素以提供约0.001 µg/mL至约10 µg/mL的类胡萝卜素的总量。更特别地,营养组合物包含的叶黄素的量为约0.001 µg/mL至约10 µg/mL、包括约0.001 µg/mL至约5 µg/mL、包括约0.001 µg/mL至约0.0190 µg/mL、包括约0.001 µg/mL至约0.0140 µg/mL、并且还包括约0.044 µg/mL至约5 µg/mL的叶黄素。还通常优选地,营养组合物包含约0.001 μg/mL至约10 μg/mL、包括约0.001 μ g/mL至约5 μg/mL、约0.001 μg/mL至约0.0130 μ g/mL、包括约0.001 μg/mL至约0.0075 μ g/mL、并且还包括约0.0185 μg/mL至约5 μg/mL的番茄红素。还通常优选地,营养组合物包含约1 μg/mL至约10 μg/mL、包括约1 μg/mL至约5 μg/mL、包括约0.001 μg/mL至约0.025 μg/mL、包括约0.001 μg/mL至约0.011 μg/mL、并且还包括约0.034 μg/mL至约5 μg/mL的β-胡萝卜素。应当理解,这些量的β-胡萝卜素、叶黄素、玉米黄素和番茄红素的任何组合可包括在本公开的营养组合物中。其他类胡萝卜素可任选包括在本文所述的营养组合物中。本文所述的营养组合物中所包括的类胡萝卜素的任一种或全部可来自天然来源,或经人工合成。在一个特殊的实施方案中,营养组合物包含中性HMO、2'FL和番茄红素的组合。
类胡萝卜素可获自用于营养组合物中的任何已知或另外适合的物质来源,且每一个可个别地或一起提供,或以任何组合提供,且来自任意数量的来源,包括来源如含有其他维生素或矿物质与如本文所述的一种或多种类胡萝卜素组合的多种维生素预混物。叶黄素、番茄红素、β-胡萝卜素或其组合的一些适合来源的非限制性实例包括LycoVit®番茄红素(获自BASF, Mount Olive, N.J.),呈油、粉末或珠形式的Lyc-O-Mato®番茄萃取物(获自LycoRed Corp., Orange, N.J.),β-胡萝卜素、叶黄素或番茄红素(获自DSMNutritional Products, Parsippany, N.J.),FloraGLO®叶黄素(获自Kemin Health,Des Moines, Iowa),Xangold® 天然叶黄素酯(获自Cognis, Cincinnati, Ohio)和Lucarotin®β-胡萝卜素(获自BASF, Mount Olive, N.J.)。
核苷酸
除中性HMOs外,本公开的营养组合物可另外包含选自核苷、嘌呤碱基、嘧啶碱基、核糖和脱氧核糖的核苷酸和/或核苷酸前体。该核苷酸可呈单磷酸盐、二磷酸盐或三磷酸盐形式。核苷酸可为核糖核苷酸或脱氧核糖核苷酸。核苷酸可为单体、二聚或聚合(包括 RNA和DNA)核苷酸。核苷酸可以游离酸形式或以盐(优选为单钠盐)形式存在于营养组合物中。在一些实施方案中,营养组合物包括中性HMOs与核苷酸的组合以使得该组合物向最终使用者提供协同益处,如调节抗病毒免疫反应和阻抑炎症和/或改善肠道障壁完整性的协同益处。
在本公开的营养组合物中并入核苷酸提高肠道障壁完整性、成熟或二者。
适合用于营养组合物中的核苷酸和/或核苷包括以下一种或多种:5'-单磷酸胞苷、5'-单磷酸尿苷、5'-单磷酸腺苷、5'-1-单磷酸鸟苷和/或5'-单磷酸肌苷,更优选5'-单磷酸胞苷、5'-单磷酸尿苷、5'-单磷酸腺苷、5'-单磷酸鸟苷和5'-单磷酸肌苷。
可配制包含中性HMO或HMOs的营养组合物以包含蛋白质、脂肪和碳水化合物的至少一种。在许多实施方案中,营养组合物包含中性HMO或HMOs与蛋白质、碳水化合物和脂肪。尽管脂肪、蛋白质和碳水化合物的总浓度或量可依赖产品类型(即,营养配方产品)、产品形式(即,营养固体、粉末、即食型液体或浓缩液体)和预期使用者的目标饮食需求而变化,但这种浓度或量最通常在下列具体范围之一内,包括本文描述的任何其他必需脂肪、蛋白质和/或碳水化合物成分。
脂肪
除LCPUFAs外,本公开的营养组合物可包含其他一种或多种脂肪来源。适合用于本文中的其他脂肪来源包括适合用于口服营养产品中且与此类产品的基本要素和特点相容的任何脂肪或脂肪来源。最通常地,脂肪可为乳化脂肪,其浓度以重量计可为约1%至约30%、包括约2%至约15%、并且还包括约4%至约10%。在一个特殊的实施方案中,另外的脂肪衍生自短链脂肪酸。
用于本文描述的营养产品的合适的脂肪或其来源的另外非限制性实例包括椰子油、分馏椰子油、大豆油、玉米油、橄榄油、红花油、高油酸红花油、油酸(EMERSOL 6313油酸,Cognis Oleochemicals, Malaysia)、MCT油(中链甘油三酯)、向日葵油、高油酸向日葵油、棕榈和棕榈仁油、棕榈油精(palm olein)、菜籽油、海洋油(marine oils)、鱼油、真菌油、海藻油、棉籽油及其组合。花生四烯酸和二十二碳六烯酸的脂质来源包括但不限于海洋油、蛋黄油和真菌油或海藻油。
这些脂肪的许多商业来源容易获得并且是本领域技术人员已知的。例如,大豆油和菜籽油可从Archer Daniels Midland,Decatur, Ill. Corn获得,椰子油、棕榈油和棕榈仁油可从Premier Edible Oils Corporation,Portland, Organ获得。分馏椰子油可从Henkel Corporation,LaGrange, Ill获得。高油酸红花油和高油酸向日葵油可从SVOSpecialty Products,Eastlake, Ohio获得。海洋油可从Mochida International,Tokyo,Japan获得。橄榄油可从Anglia Oils,North Humberside, United Kingdom获得。向日葵油和棉籽油可从Cargil,Minneapolis, Minn获得。红花油可从California OilsCorporation,Richmond, Calif获得。
除了这些食品级油之外,如果需要,可将结构脂质加入食品中。结构脂质是本领域已知的。结构脂质的简述可在INFORM, Vol. 8, No. 10,第1004页;标题为Structuredlipids allow fat tailoring (1997年10月)中获悉。还参见第4,871,768号美国专利。结构脂质主要为包含在相同的甘油核上的中链和长链脂肪酸的混合物的三酰甘油。结构脂质和它们在肠配方产品中的用途也在第6,194,379号和第6,160,007号美国专利中描述。
任选地,ω-3脂肪酸可占高达约30%的油混合物,优选地ω-3脂肪酸主要由长链形式、二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)组成。用于制备营养组合物的膳食油通常包含甘油三酯形式的ω-3脂肪酸并且包括但不限于菜籽、中链甘油三酯、鱼、大豆、大豆卵磷脂、玉米、红花、向日葵、高油酸向日葵、高油酸红花、橄榄、琉璃苣、黑加仑、月见草和亚麻籽油。任选地,本发明的脂质混合物中ω-6脂肪酸与ω-3脂肪酸的重量比为约0.1至3.0。ω-3脂肪酸的每日递送量应为至少450 mg并且可依赖个体的体重、性别、年龄和医学状况而变化。如提及的,对于成人食用需要更高水平:例如,约0.5至50 gm每日,更优选地约2.5至5 gm每日。
蛋白质
营养产品还可包含适用于口服营养产品并且与这种产品的必需元素和特征相容的任何蛋白质或其来源。营养液中的总蛋白质浓度以重量计可为约0.5%至约30%、包括约1%至约15%、包括约2%至约10%、并且还包括约3%至约8%、包括约3%至约7%,并且包括约3%至约6.72%。在一个特殊的实施方案中,当营养产品为乳液时,乳液包含以重量计总浓度为约6.77%的蛋白质。当营养产品为基本上透明液体时,透明液体包含以重量计总浓度为约3.00%至约4.47%的蛋白质。
适合用于营养产品中的蛋白质或其来源的非限制性实例包括水解、部分水解或非水解蛋白质或蛋白质来源,其可来源于任何已知或另外适合的来源,例如乳(例如,酪蛋白、乳清)、动物(例如,肉、鱼)、谷类(例如,稻、玉米)、植物(例如,大豆)或其组合。此类蛋白质的非限制性实例包括乳蛋白分离物、如本文所述的乳蛋白浓缩物、酪蛋白分离物、高度水解酪蛋白、乳清蛋白、酪蛋白钠或酪蛋白钙、全牛乳、部分或完全脱脂乳、大豆蛋白分离物、大豆蛋白浓缩物等。在一个特定实施方案中,营养组合物包括来源于人和/或牛来源的乳蛋白的蛋白质来源。
营养产品中的蛋白质当在本文限定该术语时可包含完整蛋白质以提高产品稳定性和最小化在保质期期间制剂中苦味和余味的形成。
碳水化合物
营养组合物还可包含适用于口服营养产品并且与这类产品的必需元素和特征相容的任何碳水化合物。例如,营养液中的碳水化合物浓度以重量计可为约5%至约40%、包括约7%至约30%、包括约10%至约25%。
适合用于本文所述的营养产品中的碳水化合物或其来源的非限制性实例可包括麦芽糊精、水解或改性淀粉或玉米淀粉、葡萄糖聚合物、玉米糖浆、玉米糖浆固体、来源于稻的碳水化合物、来源于豌豆的碳水化合物、来源于马铃薯的碳水化合物、木薯、蔗糖、葡萄糖、果糖、乳糖、高果糖玉米糖浆、蜂蜜、糖醇(例如,麦芽糖醇、赤藻糖醇、山梨糖醇)、人造甜味剂(例如,蔗糖素、乙酰磺胺酸钾、甜菊)及其组合。尤其所需的碳水化合物为低右旋糖当量(DE)麦芽糊精。
其他任选成分
本公开的营养组合物可进一步包含其他任选的组分,其可改变产品的物理、化学、美观或加工特征或当用于目标群体时充当药物或其他营养组分。许多这些任选的成分为已知的或另外适合用于医学食物或其他营养产品或药物剂型中且也可用于本文的组合物中,条件是此类任选的成分对于口服给予为安全的且与所选产品形式中的基本和其他成分相容。
这种任选成分的非限制性实例包括防腐剂、乳化剂、缓冲剂、核苷酸、果寡糖、纤维、半乳寡糖、聚右旋糖和其他益生元、益生菌、药物活性物、抗炎剂、本文描述的另外营养素、着色剂、调味剂、增稠剂和稳定剂、乳化剂、润滑剂等。
营养组合物可进一步包含甜味剂,优选包括至少一种糖醇,如麦芽糖醇、赤藻糖醇、山梨糖醇、木糖醇、甘露糖醋、异麦芽酮糖醇(isolmalt)和乳糖醇,且也优选包括至少一种人造或高效力甜味剂,如乙酰磺胺酸钾、阿斯巴甜、蔗糖素、糖精、甜菊和塔格糖。这些甜味剂,尤其是糖醇与人造甜味剂的组合,尤其用于调配具有所需有利特性(profile)的本公开液体饮料实施方案。这些甜味剂组合尤其有效掩蔽有时与液体饮料中添加植物蛋白相关的不当味道。以营养产品的重量计,营养产品中任选的糖醇浓度的范围可为至少0.01%,包括约0.1%至约10%,且也包括约1%至约6%。以营养产品的重量计,任选的人造甜味剂浓度的范围可为约0.01%,包括约0.05%至约5%,也包括约0.1%至约1.0%。
流动剂或防结块剂可包括于如本文所述的营养组合物中以延缓粉末随时间凝块或结块并使得粉末实施方案容易自其容器流出。已知或另外适合用于营养粉或产品形式中的任何已知流动剂或防结块剂适用于本文,其非限制性实例包括磷酸三钙、硅酸盐及其组合。营养组合物中流动剂或防结块剂的浓度视产品形式、其他所选成分、所需流动性质等而变化,但以营养组合物的重量计,最通常在约0.1%至约4%的范围内,包括约0.5%至约2%。
稳定剂也可包括于营养组合物中。已知或另外适合用于营养组合物中的任何稳定剂也适用于本文,其一些非限制性实例包括胶,如黄原胶。以营养组合物的重量计,稳定剂可占约0.1%至约5.0%,包括约0.5%至约3%,包括约0.7%至约1.5%。
营养组合物可进一步包含各种其他维生素或相关营养素中的任一种,其非限制性实例包括维生素A、维生素D、维生素E、维生素K、硫胺素、核黄素、吡哆醇、维生素B12、类胡萝卜素(例如,β-胡萝卜素、玉米黄素、叶黄素、番茄红素)、烟酸、叶酸、泛酸、生物素、维生素C、胆碱、肌醇、其盐和衍生物及其组合。食品优选地包括但不限于下列维生素和矿物质:钙、磷、钠、氯、镁、锰、铁、铜、锌、硒、碘、铬、钼、条件必需营养素m-肌醇、肉碱和牛磺酸,以及维生素A、C、D、E、K和B复合物及其混合物。
条件必需营养素肉碱为从蛋氨酸和赖氨酸形成的天然存在的氨基酸。它的主要代谢作用与运输长链脂肪酸穿过线粒体膜有关,因此刺激这些燃料物质的氧化用于代谢能量。肉碱补充是疾病状态如肝和肾病以及主要的慢性疾病或广泛损伤并发营养不良中的重要代谢工具。任选地,可使用含量足以供给高达4 gm/天肉碱的肉碱补充正餐替代品。
营养组合物还可包含各种其他另外的矿物质中的任一种,其非限制性实例包括钙、磷、镁、铁、锌、锰、铜、钠、钾、钼、铬、氯及其组合。
正餐替代品还可包含纤维和稳定剂。纤维和/或稳定剂的合适来源包括但不限于,黄原胶、瓜尔胶、阿拉伯树胶、印度胶、刺梧桐胶、黄芪胶、琼脂、红藻胶、结冷胶、刺槐豆胶、果胶、低和高甲氧基果胶、燕麦和大麦葡聚糖、角叉菜胶、车前草、明胶、微晶纤维素、CMC(羧甲基纤维素钠)、甲基纤维素羟丙基甲基纤维素、羟丙基纤维素、DATEM(甘油单酯和甘油二酯的二乙酰基酒石酸酯)、右旋糖酐、角叉菜胶、FOS(果寡糖)及其混合物。可使用可溶膳食纤维的许多商业来源。例如,阿拉伯树胶、水解羧甲基纤维素、瓜尔胶、果胶以及低和高甲氧基果胶可从TIC Gums, Inc.,Belcamp, Md获得。燕麦和大麦葡聚糖可从Mountain LakeSpecialty Ingredients, Inc.,Omaha, Nebr获得。车前草可从Meer Corporation,NorthBergen, N.J.获得,同时角叉菜胶可从FMC Corporation,Philadelphia, Pa获得。
加入的纤维还可为不溶性膳食纤维,其代表性实例包括燕麦壳纤维、豌豆壳纤维、大豆壳纤维、大豆子叶纤维、甜菜纤维、纤维素和玉米糠。还可使用许多不溶性膳食纤维的来源。例如,玉米糠可从Quaker Oats,Chicago, Ill.获得;燕麦壳纤维来自CanadianHarvest,Cambridge, Minn.;豌豆壳纤维来自Woodstone Foods,Winnipeg, Canada;大豆壳纤维和燕麦壳纤维来自The Fibrad Group,LaVale, Md.;大豆子叶纤维来自ProteinTechnologies International,St. Louis, Mo.;甜菜纤维来自Delta Fiber Foods,Minneapolis, Minn.且纤维素来自James River Corp.,Saddle Brook, N.J。
纤维和它们结合在食品中的实例的更详细讨论可在Garleb等人发出的第5,085,883号美国专利中获悉。
在配方产品中使用的纤维的量可变化。使用的纤维的特定类型并不关键。可使用适于人食用并且在食品基质中稳定的任何纤维。
除了纤维之外,营养组合物还可包含寡糖如果寡糖(FOS)或半乳寡糖(GOS)。寡糖通过寄居在大肠的厌氧微生物迅速和广泛发酵成短链脂肪酸。这些寡糖对于大多数双歧杆菌属(Bifidobacterium)种是优先能源,但不能被潜在致病生物体如产气荚膜梭菌(Clostridium perfingens)、艰难梭菌(C. difficile)或大肠杆菌(Eschericia coli)使用。
营养产品可另外包含一种或多种增稠剂(即,增稠试剂)。添加增稠剂通过诱导饱腹感觉,其延长上述胃通过时间,减少感觉异常的发病率。
示例性增稠剂包括阿拉伯树胶、羧甲基纤维素钠、甲基纤维素、瓜尔胶、结冷胶、刺槐豆胶、魔芋粉、羟丙基甲基纤维素、黄芪胶、刺梧桐胶、阿拉伯树胶、壳聚糖、阿拉伯半乳聚糖(arabinogalactin)、葡甘露聚糖、黄原胶、海藻酸盐、果胶、低和高甲氧基果胶、谷物β-葡聚糖(即,燕麦β-葡聚糖、大麦β-葡聚糖)、角叉菜胶和车前草。
用于营养液的一种特别优选的增稠剂为结冷胶。结冷胶为由假单胞杆菌伊乐藻属(Pseudomonas elodea)产生的水溶性多糖。由于结冷胶为剪切稀化的,因此它可用于营养液而不产生粘性、无吸引力质地的产品。特别优选用于本公开的营养产品包括低酰基结冷胶。“低酰基”结冷胶(还称为并且通常称为去乙酰基结冷胶)意指结冷胶已被处理使得与形成软、非常弹性、非易碎凝胶的“高酰基”相比,它形成热稳定的坚固、无弹性、易碎凝胶。一种合适的市售低酰基结冷胶为Kelcogel F(CP Kelco U.S. Inc., Atlanta Georgia)。
增稠剂,且特别地结冷胶以营养液重量计,约0.03%至约0.05%、包括约0.035%至约0.045%并且包括约0.04%的浓度存在于营养液中。
本公开的粉末营养组合物中的脂肪、碳水化合物和蛋白质的总量或浓度可显著依赖选择的组合物和预期使用者的膳食或医学需求而变化。大量营养素浓度的另外合适的实例在下面阐述。
产品形式
可以任何已知或另外合适的口服产品形式配制和给予本公开的营养组合物。任何固体、液体、半固体和半液体或粉末产品形式,包括其组合或变型适于在本文使用,条件是这种形式允许安全和有效的口服递送至个体也在本文定义的必需成分。
营养组合物可为包含本文描述的成分,并且对于口服给药安全和有效的任何产品形式。可配制营养组合物仅包含本文描述的成分,或者可使用任选成分修改以形成许多不同的产品形式。
本公开的营养组合物适宜配制成膳食产品形式,其在本文中定义为呈产品形式的包含本公开成分的那些实施方案,其于是含有脂肪、蛋白质和碳水化合物中的至少一种,且优选还含有维生素、矿物质或其组合。营养组合物将包含至少中性HMOs,适宜地与蛋白质、脂肪、维生素和矿物质中的至少一种组合以产生营养组合物。
营养组合物可配制成含有足够种类和量的营养素以提供营养的唯一、主要或补充来源,或提供用于患有特定疾病或疾病状态的个体的特定营养产品或如下文所述的目标营养益处。
适用于本文使用的营养组合物形式的实例包括零食和正餐替代品,包括配制为棒、条、曲奇或面包或蛋糕或其他烘烤食品、冷冻液体、糖果、早餐谷物、粉末或颗粒固体或其他颗粒、零食薯片或小食、冷冻或蒸煮主菜等的那些。营养组合物还可为介于固体和液体之间的形式,例如半固体或半液体组合物如布丁或凝胶。
适用于本文使用的液体产品形式的实例包括零食和正餐替代品,热或冷饮料、充气或非充气饮料、果汁或其他酸性饮料、乳或大豆基饮料、奶昔(shake)、咖啡、茶、用于通过鼻胃管置入给予的组合物等。这些液体组合物最通常配制为悬浮液或乳液,但还可以配制为任何其他合适的形式如透明液体、基本上透明的液体、液体凝胶等。
营养组合物包含一种或多种帮助满足患者的营养需求的成分。任选的营养素可提供多达约1000 kcal的能量每份或剂量,包括约25至约900 kcal、约75至约700 kcal、约150至约500 kcal、约350至约500 kcal或约200至约300 kcal。
大多数正餐替代品(即,棒或液体)提供来自脂肪、碳水化合物和蛋白质的热量。这些产品还通常包含维生素和矿物质,因为它们意图适于用作唯一的营养来源。尽管这些正餐替代品可充当唯一的营养来源,但它们通常不是。个体食用这些产品以代替一天的一或两餐,或提供健康零食。本发明的营养产品应理解为包括这些实施方案的任一个。
这些营养成分的量可依赖目标患者群体(即,癌症、HIV/AIDS、关节炎、感官考虑、文化偏好、需要等)而广泛变化。然而,作为一般非限制性指标,本发明的正餐替代品包含下列相对量的蛋白质、脂肪和碳水化合物(基于总热量的相对百分比):提供5至80%的总热量含量的蛋白质组分、提供10至70%的总热量含量的碳水化合物组分,和提供5至50%的总热量含量的脂质组分。
正餐替代品包含制备营养配方产品领域的技术人员已知的合适的碳水化合物、脂质和蛋白质。合适的碳水化合物包括但不限于来源于玉米、木薯、稻或马铃薯的蜡状或非蜡状形式的水解、完整、天然和/或化学改性的淀粉;和糖如葡萄糖、果糖、乳糖、蔗糖、麦芽糖、高果糖玉米糖浆、玉米糖浆固体、果寡糖(FOS)及其混合物。
通常,FOS占0至5 gm/份的正餐替代品,优选地1至5 gm/份、更优选地2至4 gm/份的正餐替代品。
正餐替代品可使用本领域技术人员熟知的技术制备。存在许多加工技术。通常,这些技术包括从一种或多种溶液形成浆料,其可包含水和下列的一种或多种:碳水化合物、蛋白质、脂肪、稳定剂、维生素和矿物质。通常,在其他矿物质之前将中性HMO添加至碳水化合物浆料。将浆料乳化、均质化和冷却。可在加工之前、加工之后或在两个时间将许多其他溶液添加至浆料。然后,将加工的配方产品灭菌并可稀释以被干燥成粉末,基于即食使用或以浓缩液体形式包装。当产生的配方产品意指即食液体或浓缩液体时,在灭菌之前添加适当量的水。
固体组合物如棒、曲奇等也可使用本领域技术人员已知的技术制备。例如,可使用本领域已知的冷挤出技术制备它们。为了制备这种组合物,通常将所有粉末组分干混合在一起。这种成分通常包含蛋白质、维生素预混物,某些碳水化合物等。然后,将脂溶性组分混合在一起并与上述粉末预混物混合。最终,然后将任何液体成分混入组合物中,形成塑料样组合物或面团。
上述过程意图通过称为冷成型或挤出的程序提供然后可被成形而不发生其他物理或化学变化的塑性体。在该过程中,塑性体在相对低的压力下被迫通过模具,其给予期望的形状。然后,将产生的挤出物在适当位置切割以提供期望重量的产品。如果需要,然后将固体产品包衣以增强适口性并且包装用于分配。通常,包装提供最终消费者(即,待被癌症患者食用以帮助最小化瘦肌肉损失等)使用说明书。
还可通过烘烤应用或热挤出制备本发明的固体组合物以制备谷类、曲奇和薄脆饼干。本领域技术人员能够选择制备期望的最终产品可用的许多制备方法之一。
如上所述,还可将中性HMOs加入果汁、非充气饮料、充气饮料、电解质溶液、加味水(下文共同为“饮料”)等中。制备这种饮料的方法是本领域熟知的。读者注意力指向第5,792,502号美国专利,其各自的内容通过引用由此并入。例如,将包含中性HMOs的所有成分溶于适当量的水中。然后,任选添加调味剂、着色剂、维生素等。然后,将混合物巴氏消毒、包装和储存直至出货。
适用于本文公开的包含中性HMO的组合物的产品形式的具体非限制性实例包括例如,液体和粉末膳食补充剂。
营养液
营养液包含浓缩和即食型营养液二者。最通常,这些营养液配制为悬浮液或乳液,尽管其他液体形式在本公开的范围内。通常,可将中性HMOs加入正餐替代饮料中如Ensure®、Glucerna®等。还可将中性HMOs加入EAS液体运动营养产品中。或者,可将中性HMOs加入果汁、充气饮料、瓶装水等中。此外,可将中性HMOs加入医学营养品中,如设计为支持特殊疾病状态如癌症、HIV/AIDS、COPD关节炎等的ProSure®、Promote®、Jevity®和Advera®。制备任何这种食品的方法是本领域技术人员熟知的。
当营养产品为浓缩营养液时,浓缩营养液中的中性HMOs的总浓度,以浓缩营养液的重量计为约0.0002%至约0.60%、包括约0.002%至约0.30%、包括约0.02%至约0.20%,并且还包括约0.02%至约0.06%。
当营养产品为即食型营养液时,即食型营养液中的中性HMOs的总浓度,以即食型营养液的重量计为约0.0001%至约0.50%、包括约0.001%至约0.15%、包括约0.01%至约0.10%,并且还包括约0.01%至约0.03%。
适于使用的营养乳液可为包含蛋白质、脂肪和碳水化合物的水性乳液。这些乳液在约1℃至约25℃下通常为可流动或可饮用液体,并且通常为水包油、油包水、或复合水性乳液形式,尽管这种乳液最通常为具有连续水相和不连续油相的水包油乳液形式。
营养乳液可为并且通常为贮存稳定的。营养乳液通常包含多达约95重量%的水,包括约50%至约95%、还包括约60%至约90%、并且还包括约70%至约85%的水,以营养乳液的重量计。营养乳液可具有多种产品密度,但最通常具有大于约1.03 g/mL、包括大于约1.04 g/mL、包括大于约1.055 g/mL、包括约1.06 g/mL至约1.12 g/mL、并且还包括约1.085 g/mL至约1.10 g/mL的密度。
营养乳液可具有适合最终使用者的营养需求的热量密度,尽管在大多数情况下,乳液通常包含至少15 kcal/fl oz(540 kcal/升)、更通常约27.5 kcal/fl oz(928 kcal/升)至约44 kcal/fl oz(1475-1480 kcal/升)。在一些实施方案中,乳液可具有约500kcal/升至约3000 kcal/升、包括约540 kcal/升至约2000 kcal/升的热量密度。在一些具体的实施方案中,乳液可具有500或900或1200或1500或2000 kcal/升的热量密度。
营养乳液可具有约2.5至约8的pH,但最有利地为约4.5至约7.5、包括约5.5至约7.3、包括约6.2至约7.2。
尽管营养乳液的食用份量可依赖许多变量而变化,但典型的食用份量通常为至少约1 mL,或甚至至少约2 mL、或甚至至少约5 mL、或甚至至少约10 mL、或甚至至少约25 mL、包括约1 mL至约360 mL、包括约30 mL至约250 mL,并且包括约60 mL至约240 mL。
优选的液体营养组合物包括Ensure® Muscle Health和Ensure® ClinicalStrength,其二者可从Abbott Nutrition(Columbus, OH)获得。Ensure® ClinicalStrength(Ensure® CS)的组合物的非限制性实例在下面表1和2中描述,此后立即提供具体成分。
表1:产品信息
表2:产品信息
在特殊的实施方案中,营养补充剂包括水、玉米糖浆、蔗糖、乳蛋白浓缩物、酪蛋白钠、菜籽油、玉米油、果寡糖、大豆蛋白分离物、2'-岩藻糖基乳糖、乳清蛋白浓缩物、柠檬酸钾、天然和人工调味剂、磷酸钾、卵磷脂、纤维素凝胶、氢氧化镁、碳酸钙、抗坏血酸、磷酸钙、氯化胆碱、氯化钠、磷酸钠、氢氧化钾、硫酸锌、纤维素树胶、L-肉碱、角叉菜胶、dl-α-生育酚乙酸酯、右旋糖、硫酸亚铁、麦芽糊精、烟酰胺、结冷胶、泛酸钙、柠檬酸、硫酸铜、硫酸锰、氯化铬、氯化硫胺素盐酸盐、椰子油、维生素A棕榈酸酯、盐酸吡哆醇、核黄素、叶酸、生物素、硒酸钠、钼酸钠、碘化钾、叶绿醌、氰钴胺素和维生素D3。
营养固体
营养固体可为任何固体形式,但通常为可流动或基本上可流动颗粒组合物,或至少颗粒组合物形式。特别合适的营养固体产品形式包括喷雾干燥的、聚结的和/或干掺合的粉末组合物。组合物可容易地舀取并可使用勺子或类似其他设备测量,并且可由预期使用者使用合适的水性液体通常水容易地重构以形成用于立即口服或肠使用的营养组合物。在该上下文中,“立即”使用通常意指在约48小时内,最通常在约24小时内,优选在重构后立即。
当营养产品为营养粉时,以营养粉的重量计,营养粉中的中性HMOs的总浓度为约0.0005%至约5%、包括约0.01%至约1%。
在使用前,可使用水将营养粉重构至适合最终使用者的营养需求的热量密度,尽管在大多数情况下,使用水将粉末重构以形成包含通常至少15 kcal/fl oz(540 kcal/升)、更通常为约27.5 kcal/fl oz(928 kcal/升)至约44 kcal/fl oz(1475-1480 kcal/升)的组合物。在一些实施方案中,乳液可具有约500 kcal/升至约3000 kcal/升、包括约540 kcal/升至约2000 kcal/升的热量密度。在一些特殊的实施方案中,乳液可具有500或900或1200、或1500、或2000 kcal/升的热量密度。
在其他实施方案中,可将中性HMOs加入饮料、棒、曲奇等中,其被特别设计以增强中性HMOs的适口性和增加替代形式的选择,由此提高患者/消费者接受度。可将中性HMOs加入正餐替代或零食棒中如Glucerna®棒、ZonePerfect®棒和EAS® Sports Nutrition棒等。制备任何这种食品的方法是本领域技术人员熟知的。下列讨论意图例示这种食品和它们的制备。
在以棒的形式提供营养组合物时,营养棒可包含至少一种约0.01 mg/棒至约10g/棒、包括约0.01 mg/棒至小于2 g/棒、并且还包括0.1 mg/棒至约10 g/棒、包括约0.1mg/棒至小于2 g/棒的量的中性人乳寡糖。
优选的棒营养组合物包括Glucerna® Hunger Smart棒、Glucerna® Snack棒、Glucerna® Meal Replacement棒、ZonePerfect ®棒、EAS® Lean 15™ 棒和EAS®Myoplex 30™棒,其均可从Abbott Nutrition(Columbus, OH)获得。Glucerna® HungerSmart巧克力片零食棒的示例性组合物在下面表3中描述,此后立即提供具体成分。
表3. Glucerna Hunger Smart产品实例信息
食用份量– 1棒
<i>量每份</i> | %DV | |
热量 | 140 | |
来自脂肪的热量 | 40 | |
总脂肪 | 4.5g | 7% |
饱和脂肪 | 2.5g | 13% |
n3-LCPUFA | 0.2g | |
反式脂肪 | 0 g | |
胆固醇 | 0 mg | 0% |
钠 | 180 mg | 8% |
钾 | 70 mg | 2% |
总碳水化合物 | 20g | 7% |
膳食纤维 | 3g | 12% |
糖 | 5g | |
2-岩藻糖基乳糖 | 0.12g | |
糖醇 | 8g | |
蛋白质 | 10 g | 20% |
维生素A | 15% | |
钙 | 15% | |
维生素E | 100% | |
维生素C | 20% | |
铁 | 10% | |
铬 | 30% |
在本发明的具体示例性实施方案中,上述显示的Glucerna® Hunger Smart巧克力片零食棒包括:大豆蛋白质片、巧克力味糖衣果汁和谷物糊精、棉花糖粘结剂、果糖液体、巧克力味片、大豆蛋白分离物、玉米麦芽糊精、短链果寡糖、2-岩藻糖基乳糖、甘油、高油酸红花油和巧克力层。
制备方法
本公开的营养组合物可通过用于制备所选产品固体或液体形式的任何已知或另外有效制造技术来制备。已知用于任何给定产品形式(如营养液或营养粉)的许多此类技术且其可容易由本领域普通技术人员应用于本文所述的营养组合物。
因此,本公开的营养组合物可通过各种已知或另外有效配制或制造方法中的任一种来制备。在一种适合的制造方法中,例如制备至少三种个别的浆料,包括脂肪包蛋白质(protein-in-fat,PIF)浆料、碳水化合物-矿物质(CHO-MIN)浆料和水包蛋白质(protein-in-water,PIW)浆料。PIF浆料通过加热和混合油(例如,菜籽油、玉米油等),然后在持续加热和搅拌下添加乳化剂(例如,卵磷脂)、脂溶性维生素和一部分总蛋白质(例如,乳蛋白浓缩物等)来形成。CHO-MIN浆料通过在加热搅拌下将以下添加至水中来形成:矿物质(例如,柠檬酸钾、磷酸氢二钾、柠檬酸钠等)、痕量和超痕量矿物质(TM/UTM预混物)、增稠剂或悬浮剂(例如微晶粉末纤维素、结冷胶、角叉菜胶)。所得的CHO-MIN浆料在持续加热和搅拌下保持 10分钟,然后添加其他矿物质(例如,氯化钾、碳酸镁、碘化钾等)和/或碳水化合物(例如,中性HMOs、果寡糖、蔗糖、玉米糖浆等)。然后PIW浆料通过在加热和搅拌下与其余蛋白质(若存在)混合来形成。
然后将得到的浆料在加热搅拌下掺合在一起并将pH调至6.6-7.0,随后对组合物进行高温短时(HTST)处理,在此期间将组合物热处理、乳化和均质化,然后使其冷却。添加水溶性维生素和抗坏血酸,必要时将pH调至所需范围,添加调味剂,并添加水以达到所需的总固体水平。接着无菌包装组合物以形成无菌包装的营养乳液。然后可进一步稀释、热处理和包装该乳液以形成即食型或浓缩液体,或可将其热处理并随后加工和包装成可重构粉末,例如喷雾干燥、干混、聚结粉末。
营养固体如喷雾干燥的营养粉或干混的营养粉可通过适于制备和配制营养粉的任何已知或另外有效技术的集合来制备。
例如,当营养粉为喷雾干燥的营养粉时,喷雾干燥步骤可同样包括已知或另外适合用于制造营养粉的任何喷雾干燥技术。已知许多不同喷雾干燥方法和技术用于营养领域,其全部均适合用于制造本文的喷雾干燥的营养粉。
一种制备喷雾干燥的营养粉的方法包括形成和均质化预先消化的脂肪和任选蛋白质、碳水化合物和其他脂肪来源的水性浆料或液体,然后喷雾干燥该浆料或液体以产生喷雾干燥的营养粉。该方法可进一步包括喷雾干燥、干混或另外向喷雾干燥的营养粉中添加其他营养成分(包括本文所述的任一种或多种成分)的步骤。
其他适合用于制备营养产品的方法例如描述于美国专利第6,365,218号(Borschel等)、美国专利第6,589,576号 (Borschel等)、美国专利第6,306,908号(Carlson等)、美国专利申请20030118703 A1 (Nguyen等)中,其描述在其据此一致的程度上以引用的方式并入本文中。制备营养棒的方法在美国专利6,248,375中描述,并且该描述在其据此一致的程度上以引用的方式并入本文中。
使用方法
本文描述的营养组合物可用于解决一种或多种本文讨论的疾病或疾病状态,或可用于提供成人和老年个体一种或多种本文描述的益处。使用本文描述的营养组合物的成人或老年个体实际上可具有或患有描述的疾病或疾病状态,或可易于患有所述疾病或疾病状态、或处于获得所述疾病或疾病状态的风险(即,实际上可能尚未具有疾病或疾病状态,但于一般群体相比,由于一些疾病状态家族史等处于获得它的高风险)。不论成人或老年个体实际上是否具有疾病或疾病状态,或者处于患疾病或疾病状态的风险或易患疾病或疾病状态,在本文将成人或老年个体分类为“需要”帮助处理和抗击疾病或疾病状态。例如,成人或老年个体实际上可具有呼吸道炎症或可处于获得呼吸道炎症的风险(易患呼吸道炎症),例如由于家族病史或其他医学疾病状态。不论成人或老年个体实际上是否具有疾病或疾病状态,或者仅处于患疾病或疾病状态的风险或易于获得疾病或疾病状态,在本公开的范围内使用本文描述的营养组合物帮助成人或老年个体。
此外,单独地或与另一中性HMO(例如,3FL)组合的2'FL适用于小儿、成人产品和老年人群体,在需要降低炎症的情况下。需要的群体包括那些:在微生物感染中(呼吸道或胃肠感染;败血症;牙周炎;处于NEC的风险;处于血管炎症的风险;处于增加的PNC形成的风险(糖尿病女性、缺血患者、活性镰状细胞病);处于慢性炎症的风险(老年人、过敏症/哮喘、IBD、NEC)。
基于前述,由于本公开的一些方法实施方案涉及识别的个体的特定亚群或亚类(即,“需要”帮助解决一种或多种本文指出的特定疾病或特定疾病状态的个体的亚群或亚类),并非所有成人或老年个体均落入本文针对一些疾病或疾病状态描述的成人或老年个体的亚群或亚类的范围内。
本文描述的营养组合物包含单独地或与一种或多种另外组分组合的中性HMOs以提供用于减少炎症,例如呼吸道炎症(例如,呼吸道合胞体病毒诱导的炎症)、肠炎症、鼻咽炎症和全身炎症的营养来源。
此外,在营养组合物中使用中性HMOs可减少呼吸道病毒(例如,RSV、人副流感病毒类型2和甲型流感病毒)的生长,因此减少病毒-诱导的上呼吸道感染。
本公开的营养组合物的使用还充当免疫调节剂,由此减少由成人和老年人群体中的感染诱导的炎症,例如呼吸道病毒-诱导的感染,且特别地,RSV-诱导的炎症和其他感染-介导的炎性疾病。
当与LCPUFAs和/或抗氧化剂组合,且特别地,与类胡萝卜素组合使用时,中性HMOs可减少氧化应激,其为代谢状态,其中存在氧化生物分子的产生和累积增加,如脂质过氧化物和它们的分解代谢物、蛋白羰基和氧化损伤的DNA。氧化应激的结果范围从代谢的不期望变化到炎症以及细胞和组织死亡。因此,通过减少未调节的炎症和氧化的发生率,对组织衬里的损伤和细胞死亡减少,进一步减少炎性疾病的发病率。
除了上述讨论的益处之外,发现包含中性HMOs的营养产品可调节单核细胞-衍生的细胞因子的产生,即使在没有病毒的情况下。该产生导致提高的免疫力以进一步最小化微生物感染和减少病毒生长。在一个特殊的实施方案中,通过给予本公开的营养组合物产生的单核细胞-衍生的细胞因子包括例如,白介素-10、白介素-8、白介素-1α、白介素-1β、白介素-1ra及其组合。
在营养组合物中使用中性HMOs的另一益处在于已经发现中性HMOs调节IP-10的产生,其为在对病毒感染的炎性反应中发挥重要作用的趋化因子。具体地,在RSV临床感染严重程度和血清IP-10水平之间存在正相关。因此,IP-10的减少标志RSV感染严重程度的降低。在一个特殊的实施方案中,将IP-10产生减少至在未感染的对照中发现的水平。
连同减少IP-10,发现中性HMOs减少血小板-嗜中性粒细胞复合物(PNC)形成,其存在于人血液中并且包括高达25%的未刺激的嗜中性粒细胞。由于PNCs以聚集体形式存在,因此它们具有更大的能力开始炎性过程并且可增加活性氧物种的产生。因此,PNC形成的减少可导致减少的氧化应激和炎症。
实施例
下列实施例例示本公开营养组合物的具体实施方案、特征,或二者。提供实施例仅为了例示目的并且不被理解为本公开的限制,因为在不违背本公开的主旨和范围情况下其许多变型是可能的。所有实施例量为基于组合物总重量的重量百分比,除非另外规定。
实施例组合物为根据本文描述的制备方法制备的贮存稳定的营养组合物,使得各个实施例组合物,除非另外规定,包括无菌处理的实施方案和蒸煮包装的实施方案。
实施例1
使用PNC形成的体外刺激,用15分钟成分孵育时间段产生数据。
中性HMOs
图1中示出的结果表明浓度为125 µg/mL的单独的2'FL以及FL Mix(70% 2'FL:30% 3FL= 87.5 µg 2'FL /mL:37.5 µg 3FL/mL)显著减少PNC形成。图1中的数据(n=2-3个体)出乎意料地显示单独的或作为FL Mix (70% 2'FL:30% 3FL = 87.5 ug 2'FL /mL:37.5 ug3FL/mL)的一部分的2'FL通过减少PNC形成而减少炎症。这是出乎意料的,因为公开的信息表明合并的中性HMOs(其包含2'FL和3FL)并不减少PNC形成。
酸性HMOs
我们的数据还显示单独的酸性HMOs 3'SL和6'SL并不减少PNC形成;并且唾液酸(SL)也不减少PNC形成。这是出乎意料的,因为在先数据显示合并的酸性HMOs减少PNC形成。
实施例2
中性HMOs 2'FL和LNnT减少PNC形成
当来自该PNC实验的选择的数据由供体和成分(如表4所示)详细说明时,我们看出2'FL减少所有3名测试的个体中的PNC形成。还明显地是LNnT减少2/3测试的主体中的PNC形成。对于所有测试的成分,测试浓度为125 µg/mL。使用测试成分或单独的介质(ADP)将细胞孵育15分钟。将ADP(10 µM)添加至各个管并孵育15分钟。单独的ADP不含测试成分。将数据表示为在测试条件下的% CD11b+CD42a+,作为在ADP刺激下是CD11b+CD42a+的那些事件的百分比。2'FL和LNnT的平均反应显示这些成分具有最低的%CD11b+CD42a+值,表明PNC形成的最大减少。
表4
在测试条件下的% CD11b+CD42a+,作为在ADP刺激下是CD11b+CD42a+的那些事件的百分比:
实施例3
实施例3例示了包含HMOs的本公开的乳液,其成分在下面表格中列出。以磅每约1000磅批次产品形式列出所有成分量,除非另外规定。
成分 | lb/1000lbs |
水 | Q.S. |
乳蛋白浓缩物 | 66.6 |
蔗糖 | 51.3 |
麦芽糊精 | 36.0 |
大豆蛋白分离物 | 15.9 |
大豆油 | 12.5 |
HMO | 0.2 |
玉米油 | 5.89 |
柠檬酸钾 | 4.48 |
菜籽油 | 4.17 |
微粉化-磷酸三钙 | 2.40 |
柠檬酸钠 | 2.02 |
氯化镁 | 1.88 |
磷酸氢镁 | 1.55 |
调味剂 | 1.50 |
LCPUFA | 1.05 |
氯化钠 | 1.00 |
大豆卵磷脂 | 0.982 |
氯化胆碱 | 0.540 |
抗坏血酸 | 0.420 |
结冷胶 | 0.400 |
UTM/TM预混物 | 0.301 |
硫酸锌,一水合物 | 0.068450 |
硫酸亚铁,干燥的 | 0.053460 |
硫酸锰,一水合物 | 0.016990 |
硫酸铜,五水合物 | 0.009248 |
氯化铬,六水合物 | 0.000573 |
钼酸钠,二水合物 | 0.000463 |
硒酸钠,无水 | 0.000191 |
45% KOH | 0.250 |
氢氧化钾 | 0.1126 |
角叉菜胶 | 0.350 |
水溶性维生素预混物 | 0.0727 |
烟酰胺 | 0.02726 |
泛酸钙 | 0.01763 |
氯化硫胺素盐酸盐 | 0.004504 |
盐酸吡哆醇 | 0.004337 |
核黄素 | 0.003519 |
叶酸 | 0.000611 |
生物素 | 0.0005311 |
氰钴胺素 | 0.00001203 |
维生素DEK预混物 | 0.0644 |
dl-α-生育酚乙酸酯 | 0.05392 |
叶绿醌 | 0.00008012 |
维生素D3 | 0.00001308 |
维生素A棕榈酸酯 | 0.00825 |
碘化钾 | 0.000206 |
实施例4
实施例4例示了包含HMOs的本公开的乳液,其成分在下面表格中列出。以磅每约1000磅批次的产品形式列出所有成分量,除非另外规定。
成分 | lb/1000lbs |
水 | Q.S. |
乳蛋白浓缩物 | 61.6 |
蔗糖 | 51.4 |
麦芽糊精 | 36.0 |
大豆蛋白分离物 | 14.7 |
大豆油 | 10.9 |
乳清蛋白磷脂浓缩物 | 9.47 |
HMO | 0.5 |
玉米油 | 5.19 |
柠檬酸钾 | 4.48 |
菜籽油 | 3.68 |
微粉化-磷酸三钙 | 2.40 |
柠檬酸钠 | 2.02 |
氯化镁 | 1.88 |
磷酸氢镁 | 1.55 |
调味剂 | 1.50 |
LCPUFA | 1.05 |
氯化钠 | 1.00 |
大豆卵磷脂 | 0.865 |
氯化胆碱 | 0.540 |
抗坏血酸 | 0.420 |
UTM/TM预混物 | 0.301 |
硫酸锌,一水合物 | 0.068450 |
硫酸亚铁,干燥的 | 0.053460 |
硫酸锰,一水合物 | 0.016990 |
硫酸铜,五水合物 | 0.009248 |
类胡萝卜素 | 0.000001 |
氯化铬,六水合物 | 0.000573 |
钼酸钠,二水合物 | 0.000463 |
硒酸钠,无水 | 0.000191 |
45% KOH | 0.250 |
氢氧化钾 | 0.1126 |
角叉菜胶 | 0.350 |
水溶性维生素预混物 | 0.0727 |
烟酰胺 | 0.02726 |
泛酸钙 | 0.01763 |
氯化硫胺素盐酸盐 | 0.004504 |
盐酸吡哆醇 | 0.004337 |
核黄素 | 0.003519 |
叶酸 | 0.000611 |
生物素 | 0.0005311 |
氰钴胺素 | 0.00001203 |
维生素DEK预混物 | 0.0644 |
dl-α-生育酚乙酸酯 | 0.05392 |
叶绿醌 | 0.00008012 |
维生素D3 | 0.00001308 |
维生素A棕榈酸酯 | 0.00825 |
碘化钾 | 0.000206 |
实施例5
实施例5例示了包含HMOs的本公开的乳液,其成分在下面表格中列出。以磅每约1000磅批次的产品形式列出所有成分量,除非另外规定。
成分 | lb/1000lbs |
水 | Q.S. |
乳蛋白浓缩物 | 66.6 |
蔗糖 | 51.5 |
麦芽糊精 | 36.2 |
大豆蛋白分离物 | 15.9 |
大豆油 | 11.4 |
HMO | 1.0 |
玉米油 | 5.89 |
柠檬酸钾 | 4.48 |
菜籽油 | 4.17 |
微粉化-磷酸三钙 | 2.40 |
LCPUFA | 2.11 |
柠檬酸钠 | 2.02 |
氯化镁 | 1.88 |
磷酸氢镁 | 1.55 |
调味剂 | 1.50 |
氯化钠 | 1.00 |
大豆卵磷脂 | 0.865 |
氯化胆碱 | 0.540 |
抗坏血酸 | 0.420 |
UTM/TM预混物 | 0.301 |
硫酸锌,一水合物 | 0.068450 |
硫酸亚铁,干燥的 | 0.053460 |
硫酸锰,一水合物 | 0.016990 |
硫酸铜,五水合物 | 0.009248 |
氯化铬,六水合物 | 0.000573 |
钼酸钠,二水合物 | 0.000463 |
硒酸钠,无水 | 0.000191 |
45% KOH | 0.250 |
氢氧化钾 | 0.1126 |
角叉菜胶 | 0.350 |
水溶性维生素预混物 | 0.0727 |
烟酰胺 | 0.02726 |
泛酸钙 | 0.01763 |
氯化硫胺素盐酸盐 | 0.004504 |
盐酸吡哆醇 | 0.004337 |
核黄素 | 0.003519 |
叶酸 | 0.000611 |
生物素 | 0.0005311 |
氰钴胺素 | 0.00001203 |
维生素DEK预混物 | 0.0644 |
dl-α-生育酚乙酸酯 | 0.05392 |
叶绿醌 | 0.00008012 |
维生素D3 | 0.00001308 |
维生素A棕榈酸酯 | 0.00825 |
碘化钾 | 0.000206 |
实施例6
实施例6例示了包含HMOs的本公开的基本澄清的营养液,其成分在下面表格中列出。该液体具有2.9至4.0的pH并且在约18个月的保质期内保持物理稳定。以磅每约1000磅批次的产品形式列出所有成分量,除非另外规定。
成分 | lb/1000lbs |
水 | Q.S. |
蔗糖 | 78.1 |
乳清蛋白分离物 | 39.5 |
磷酸 | 1.8 |
柠檬酸 | 1.3 |
酸混合物 | 38.7 |
柠檬酸 | 1.9 |
磷酸 | 1.9 |
麦芽糊精 | 20.1 |
HMO | 0.3 |
甘氨酸 | 2.56 |
柠檬酸 | 2.00 |
调味剂 | 2.00 |
液体蔗糖素(25%) | 0.300 |
蔗糖素 | 0.0750 |
UTM/TM预混物 | 0.230 |
硫酸锌,一水合物 | 0.0521 |
硫酸亚铁,干燥的 | 0.0408 |
柠檬酸,无水 | 0.0142 |
硫酸锰,一水合物 | 0.0130 |
硫酸铜,五水合物 | 0.00710 |
氯化铬,六水合物 | 0.000430 |
钼酸钠,二水合物 | 0.000339 |
硒酸钠,无水 | 0.000146 |
水可分散的ADEK预混物 | 0.178 |
dl-α-生育酚乙酸酯 | 0.0454 |
维生素A棕榈酸酯 | 0.00421 |
叶绿醌 | 0.000127 |
维生素D3 | 0.0000231 |
类胡萝卜素 | 0.01 |
乙酰磺胺酸钾 | 0.110 |
10% DMPS消泡剂(加工助剂) | 0.0600 |
二甲基聚硅氧烷 | 0.0006 |
水溶性维生素预混物 | 0.03790 |
烟酰胺 | 0.0142 |
d-泛酸钙 | 0.00920 |
氯化硫胺素盐酸盐 | 0.00240 |
盐酸吡哆醇 | 0.00230 |
核黄素 | 0.00180 |
叶酸 | 0.000350 |
生物素 | 0.000277 |
氰钴胺素 | 0.00000630 |
着色剂 | 0.00700 |
叶酸,USP | 0.00337 |
碘化钾 | 0.000204 |
实施例7
实施例7例示了包含HMOs的本公开的基本澄清的营养液,其成分在下面表格中列出。该液体具有2.9至4.0的pH并且在约18个月的保质期内保持物理稳定。以磅每约1000磅批次的产品形式列出所有成分量,除非另外规定。
成分 | lb/1000lbs |
水 | Q.S. |
蔗糖 | 78.1 |
乳清蛋白分离物 | 39.5 |
磷酸 | 1.8 |
柠檬酸 | 1.3 |
酸混合物 | 38.7 |
柠檬酸 | 1.9 |
磷酸 | 1.9 |
麦芽糊精 | 20.1 |
HMO | 0.6 |
牛磺酸 | 2.56 |
柠檬酸 | 2.00 |
调味剂 | 2.00 |
液体蔗糖素(25%) | 0.300 |
蔗糖素 | 0.0750 |
类胡萝卜素 | 0.01 |
UTM/TM预混物 | 0.230 |
硫酸锌,一水合物 | 0.0521 |
硫酸亚铁,干燥的 | 0.0408 |
柠檬酸,无水 | 0.0142 |
硫酸锰,一水合物 | 0.0130 |
硫酸铜,五水合物 | 0.00710 |
氯化铬,六水合物 | 0.000430 |
钼酸钠,二水合物 | 0.000339 |
硒酸钠,无水 | 0.000146 |
水可分散的ADEK预混物 | 0.178 |
dl-α-生育酚乙酸酯 | 0.0454 |
维生素A棕榈酸酯 | 0.00421 |
叶绿醌 | 0.000127 |
维生素D3 | 0.0000231 |
乙酰磺胺酸钾 | 0.110 |
10% DMPS消泡剂(加工助剂) | 0.0600 |
二甲基聚硅氧烷 | 0.0006 |
水溶性维生素预混物 | 0.03790 |
烟酰胺 | 0.0142 |
d-泛酸钙 | 0.00920 |
氯化硫胺素盐酸盐 | 0.00240 |
盐酸吡哆醇 | 0.00230 |
核黄素 | 0.00180 |
叶酸 | 0.000350 |
生物素 | 0.000277 |
氰钴胺素 | 0.00000630 |
着色剂 | 0.00700 |
叶酸,USP | 0.00337 |
碘化钾 | 0.000204 |
尽管本公开详细描述了几个实施例和实施方案,但提供描述仅为了例示目的并且不被理解为限制本公开。在不违背本公开的主旨和范围情况下本文描述的实施例和实施方案的许多变型是可能的。
Claims (14)
1. 用于调节或减少需要其的成人或老年个体中的炎症的营养组合物,所述营养组合物包含至少一种浓度为约0.001 mg/mL至约25 mg/mL的中性人乳寡糖。
2.如权利要求1所述的营养组合物,其中所述至少一种中性人乳寡糖选自2'-岩藻糖基乳糖和乳酰-N-新四糖(LNnT)及其组合。
3. 如权利要求1或2所述的营养组合物,其中所述至少一种人乳寡糖为2'-岩藻糖基乳糖,且其中2'-岩藻糖基乳糖以约0.001 mg/mL至约15 mg/mL的浓度存在于营养组合物中。
4. 如权利要求1-3中任一项所述的营养组合物,其中所述至少一种人乳寡糖为2'-岩藻糖基乳糖,且其中2'-岩藻糖基乳糖以约0.050 mg/mL至约10 mg/mL的浓度存在于营养组合物中。
5. 如权利要求1-4中任一项所述的营养组合物,其中所述至少一种人乳寡糖为2'-岩藻糖基乳糖,且其中2'-岩藻糖基乳糖以约0.1 mg/mL至约10 mg/mL的浓度存在于营养组合物中。
6. 如权利要求1或2所述的营养组合物,其中所述至少一种人乳寡糖为乳酰-N-新四糖(LNnT),且其中LNnT以约0.1 mg/mL至约5 mg/mL的浓度存在于营养组合物中。
7. 如权利要求1-6中任一项所述的营养组合物,其中所述营养组合物另外包含3-岩藻糖基乳糖,其以约0.001 mg/mL至约10 mg/mL的浓度存在于营养组合物中。
8.如权利要求1-7中任一项所述的营养组合物,其中所述组合物另外包含浓度不超过营养组合物中总脂肪含量的约5%的长链多不饱和脂肪酸。
9. 如权利要求1-8中任一项所述的营养组合物,其中所述组合物另外包含浓度为约0.001 μg/mL至约10 μg/mL的类胡萝卜素。
10. 如权利要求1-9中任一项所述的营养组合物,其中所述组合物另外包含浓度为约0.001 mg/mL至约10 mg/mL的酸性人乳寡糖。
11.如权利要求1-10中任一项所述的营养组合物,其中所述组合物为合成配方产品。
12.如权利要求1-11中任一项所述的营养组合物,其中所述炎症为呼吸道病毒-诱导的炎症。
13. 用于调节需要其的成人或老年个体中的炎症的营养组合物,所述组合物包含浓度为约0.001 mg/mL至约10 mg/mL的中性人乳寡糖,浓度不超过营养组合物中总脂肪含量的约5%的长链多不饱和脂肪酸,和浓度为约0.001 μg/mL至约10 μg/mL的类胡萝卜素。
14.如权利要求13所述的营养组合物,其中所述组合物为合成配方产品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261739923P | 2012-12-20 | 2012-12-20 | |
US61/739923 | 2012-12-20 | ||
CN201380067062.8A CN104853621A (zh) | 2012-12-20 | 2013-12-20 | 使用人乳寡糖用于调节炎症的营养制剂 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380067062.8A Division CN104853621A (zh) | 2012-12-20 | 2013-12-20 | 使用人乳寡糖用于调节炎症的营养制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110679948A true CN110679948A (zh) | 2020-01-14 |
Family
ID=49943588
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380067062.8A Pending CN104853621A (zh) | 2012-12-20 | 2013-12-20 | 使用人乳寡糖用于调节炎症的营养制剂 |
CN201911070370.1A Pending CN110679948A (zh) | 2012-12-20 | 2013-12-20 | 使用人乳寡糖用于调节炎症的营养制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380067062.8A Pending CN104853621A (zh) | 2012-12-20 | 2013-12-20 | 使用人乳寡糖用于调节炎症的营养制剂 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10624916B2 (zh) |
EP (2) | EP3469912A1 (zh) |
CN (2) | CN104853621A (zh) |
CA (1) | CA2894897C (zh) |
ES (1) | ES2708771T3 (zh) |
HK (1) | HK1214479A1 (zh) |
TW (1) | TWI673052B (zh) |
WO (1) | WO2014100696A1 (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014497A1 (en) * | 2014-07-21 | 2016-01-28 | Abbott Laboratories | Nutritional powder pods containing nutritional powders with volume flowability properties |
CN106535663A (zh) * | 2014-07-21 | 2017-03-22 | 雅培制药有限公司 | 包含干混碳水化合物的营养粉末料盒 |
EP3171711A1 (en) * | 2014-07-21 | 2017-05-31 | Abbott Laboratories | Nutrient delivery system with human milk oligosaccharides |
EP3171740A1 (en) * | 2014-07-21 | 2017-05-31 | Abbott Laboratories | Nutrient delivery system comprising nutritional powder comprising phospholipids to improve wettability |
US20170203914A1 (en) * | 2014-07-21 | 2017-07-20 | Abbott Laboratories | Nutritional powder pod with extruded nutritional powder |
CN106535721A (zh) * | 2014-07-21 | 2017-03-22 | 雅培制药有限公司 | 营养粉荚体及相关方法 |
CN106659223A (zh) * | 2014-07-21 | 2017-05-10 | 雅培制药有限公司 | 具有特定抗氧化剂的营养粉末 |
EP3229812A4 (en) * | 2014-12-08 | 2018-10-03 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
US10709721B2 (en) * | 2015-03-05 | 2020-07-14 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children |
ES2960750T3 (es) | 2015-03-05 | 2024-03-06 | Glycom As | Oligosacáridos de la leche humana para el tratamiento de infecciones agudas del aparato respiratorio |
DK3349763T3 (en) | 2015-09-14 | 2021-11-15 | Glycom As | Composition for use in microbiota modulation |
BE1027078A9 (nl) * | 2019-02-25 | 2020-09-28 | Nutribam Bvba | Samenstelling, voedingssupplement en werkwijze voor het ondersteunen en/of verbeteren van de darmgezondheid |
WO2020174386A1 (en) | 2019-02-25 | 2020-09-03 | Nutribam Bvba | Composition, food supplement and method for supporting and/or improving intestinal health |
US12005083B1 (en) | 2019-06-24 | 2024-06-11 | PBM Nutritionals, LLC | Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof |
US11849747B1 (en) | 2019-06-24 | 2023-12-26 | PBM Nutritionals, LLC | Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof |
EP4132560A1 (en) * | 2020-04-06 | 2023-02-15 | Abbott Laboratories | Nutritional formulations for modulating respiratory-induced cytokines |
CA3178744C (en) * | 2020-05-13 | 2023-11-14 | Ardythe L. Morrow | Fucosylated oligosaccharides for prevention of coronavirus infection |
JP2023526271A (ja) * | 2020-05-13 | 2023-06-21 | グリコシン リミテッド ライアビリティー カンパニー | コロナウイルスによって誘導される炎症の防止および処置のための2’-フコシルラクトース |
US11285105B2 (en) * | 2020-07-28 | 2022-03-29 | Igh Naturals, Inc. | Compositions and methods for improving gastrointestinal absorption of electrolytes |
WO2022106416A1 (en) | 2020-11-23 | 2022-05-27 | Dsm Ip Assets B.V. | Edible decorative element comprising human milk oligosacchrides |
AU2021395887B9 (en) | 2020-12-11 | 2023-11-02 | Ausnutria B.V. | Increased 2'-fl production by goats |
WO2022189417A1 (en) * | 2021-03-09 | 2022-09-15 | Frieslandcampina Nederland B.V. | Aqueous composition comprising gos and hmo |
CN115044642B (zh) * | 2022-08-17 | 2022-10-28 | 北京挑战生物技术有限公司 | 一种对产气荚膜梭菌抑菌剂的抑菌效果的评价方法及其应用 |
WO2024052406A1 (en) * | 2022-09-06 | 2024-03-14 | Inbiose N.V. | Baked nutritional compositions comprising human milk oligosaccharides |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102088871A (zh) * | 2008-07-08 | 2011-06-08 | 雀巢产品技术援助有限公司 | 包含寡糖混合物的营养组合物 |
EP2455387A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
US20120172327A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US20120172319A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
US20120172307A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871768A (en) | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
US5085883A (en) | 1991-06-27 | 1992-02-04 | Abbott Laboratories | Blend of dietary fiber for nutritional products |
CN1086282C (zh) | 1995-12-15 | 2002-06-19 | 普罗克特和甘保尔公司 | 含有多磷酸盐防腐剂体系和少量黄原胶的,具有稳定的风味乳浊液/混浊乳浊液的饮料 |
ATE265207T1 (de) | 1997-02-21 | 2004-05-15 | Abbott Lab | Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis |
US5906982A (en) * | 1997-03-31 | 1999-05-25 | Abbott Laboratories | Nutritional formulations containing Lacto-N-neoTetraose |
US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
US6194379B1 (en) | 1998-05-01 | 2001-02-27 | Abbott Laboratories | Elemental enteral formula |
US6365218B1 (en) | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6248375B1 (en) | 2000-03-14 | 2001-06-19 | Abbott Laboratories | Diabetic nutritionals and method of using |
US6811801B2 (en) | 2001-12-12 | 2004-11-02 | Abbott Laboratories | Methods and compositions for brightening the color of thermally processed nutritionals |
US20090118229A1 (en) | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
EP2060257A1 (en) | 2007-11-08 | 2009-05-20 | Nestec S.A. | Prevention and treatment of secondary infections following viral infection |
US9034847B2 (en) * | 2009-07-06 | 2015-05-19 | Children's Hospital Medical Center | Inhibiting inflammation with milk oligosaccharides |
MY166946A (en) | 2010-12-31 | 2018-07-25 | Abbott Lab | Methods of using human milk oligosaccharides for improving airway respiratory health |
US9763970B2 (en) | 2010-12-31 | 2017-09-19 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US9283240B2 (en) * | 2010-12-31 | 2016-03-15 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
DK2708145T3 (en) * | 2012-09-14 | 2016-07-18 | Abbott Lab | Nutritional Compositions for Use in Methods to Modulate Corticosterone Levels in Psychologically Stressed Individuals |
EP2745705A1 (en) * | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
-
2013
- 2013-12-20 US US14/654,092 patent/US10624916B2/en active Active
- 2013-12-20 CN CN201380067062.8A patent/CN104853621A/zh active Pending
- 2013-12-20 EP EP18211343.1A patent/EP3469912A1/en not_active Withdrawn
- 2013-12-20 EP EP13818953.5A patent/EP2934190B1/en active Active
- 2013-12-20 TW TW102147669A patent/TWI673052B/zh active
- 2013-12-20 CA CA2894897A patent/CA2894897C/en active Active
- 2013-12-20 WO PCT/US2013/077152 patent/WO2014100696A1/en active Application Filing
- 2013-12-20 ES ES13818953T patent/ES2708771T3/es active Active
- 2013-12-20 CN CN201911070370.1A patent/CN110679948A/zh active Pending
-
2016
- 2016-03-07 HK HK16102590.2A patent/HK1214479A1/zh unknown
-
2020
- 2020-04-02 US US16/838,660 patent/US20200230162A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102088871A (zh) * | 2008-07-08 | 2011-06-08 | 雀巢产品技术援助有限公司 | 包含寡糖混合物的营养组合物 |
EP2455387A1 (en) * | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
US20120172327A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US20120172319A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
US20120172307A1 (en) * | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
Also Published As
Publication number | Publication date |
---|---|
TWI673052B (zh) | 2019-10-01 |
US10624916B2 (en) | 2020-04-21 |
CN104853621A (zh) | 2015-08-19 |
ES2708771T3 (es) | 2019-04-11 |
EP2934190A1 (en) | 2015-10-28 |
CA2894897C (en) | 2018-09-18 |
US20160256479A1 (en) | 2016-09-08 |
US20200230162A1 (en) | 2020-07-23 |
EP3469912A1 (en) | 2019-04-17 |
HK1214479A1 (zh) | 2016-07-29 |
TW201429477A (zh) | 2014-08-01 |
EP2934190B1 (en) | 2018-12-12 |
WO2014100696A1 (en) | 2014-06-26 |
CA2894897A1 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200230162A1 (en) | Nutritional formulations using human milk oligosaccharides for modulating inflammation | |
CN104822279B (zh) | 缓减应激症状的人乳寡糖 | |
TWI669061B (zh) | 使用人乳寡醣、維生素c及抗發炎劑以減少氧化壓力影響之方法 | |
US11160817B2 (en) | Nutritional compositions comprising neuroprotective dietary oligosaccharides | |
ES2667393T3 (es) | Oligosacáridos de leche humana para modular inflamación | |
ES2708924T3 (es) | Procedimientos de uso de oligosacáridos de la leche humana para mejorar la salud respiratoria de las vías respiratorias | |
TW201306754A (zh) | 包含人乳寡醣及核苷酸之營養組合物及其用於治療及/或預防腸病毒感染的用途 | |
ES2572831T3 (es) | Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico | |
MX2013007679A (es) | Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas. | |
EP2745705A1 (en) | Nutritional use of human milk oligosaccharides | |
ES2657744T3 (es) | Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal | |
CN104363962A (zh) | 用于使用人乳寡糖调节细胞介导的免疫的方法 | |
TW201438720A (zh) | 增強學習及記憶力之膳食寡糖 | |
US20160021921A1 (en) | Preterm infant nutritional compositions containing beta-hydroxy-beta-methylbutyric acid | |
US20160029679A1 (en) | Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women | |
EP2614724A1 (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
WO2022177965A1 (en) | Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin | |
WO2023159093A1 (en) | Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin | |
TW201233340A (en) | Human milk oligosaccharides for modulating inflammation | |
CN115397457A (zh) | 用于调节呼吸诱导的细胞因子的营养制剂 | |
TW201233343A (en) | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200114 |
|
WD01 | Invention patent application deemed withdrawn after publication |